Study outcomes
Anxiety, fatigue, pain, insomnia, Insomnia, Depression, DSM-5
The experimental protocol is described in Fig. 
Representation of treatment schedule and different times of evaluation and questionnaire completionAt T-1, all potentially eligible patients have a clinical interview according to the DSM-5 to diagnose the presence of insomnia before treatment by chemotherapy. They also complete the study questionnaires [i.e., the Insomnia Severity Index (ISI), the Pittsburgh Sleep Quality Index (PSQI), the Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)] and a sleep diary for 2 weeks. The interview, questionnaires and sleep diary constitute the baseline values before inclusion. A clinical examination, including medical history, use of analgesics (type, level, dose), lifestyle habits (work, family environment, physical activity, smoking, alcohol), is also carried out.At T0, one week after completion of the first sequence of the chemotherapy, patients have a clinical interview, complete the questionnaires and sleep diary again. If insomnia is confirmed, patients can then be included.At T1, at the end of the 3-month exercise intervention (T3) and at 6 months (T6) of the follow up period, objective sleep parameters, salivary melatonin and core body temperature rhythm are evaluated. At T1 and T3, fatigue, pain, inflammatory variables and cardiorespiratory fitness are assessed. At T3, DMS-5 interview, questionnaires and sleep diary are completed again. From T1 to T6, the level of PA is followed (Fig. 